Navigation Links
DaVita Clinical Research Completes Record Number of Renal Trials in 2007
Date:5/8/2008

Nation's Largest Renal Research Network Completes 13 Phase-I Clinical

Trials; Reports Another 34 Active Trials in Late Stage Development

EL SEGUNDO, Calif., May 8 /PRNewswire/ -- DaVita Clinical Research(R) (DCR), a Phase I-IV clinical trial research service business specializing in renal-related drug and device research and development for FDA approval, reports it completed 13 Phase-I clinical trials in 2007 and has another 34 active trials in late stage drug development-a company record.

(Logo: http://www.newscom.com/cgi-bin/prnh/20020729/DAVITALOGO)

DCR(R), through its commitment to quality, timely and accurate clinical trials, plays a valuable role by partnering with physicians, pharmaceutical and biotechnology companies to develop and progress new drug therapies for patients diagnosed with chronic kidney disease (CKD). The increase in completed and late stage trials also serves as an indication of continued innovation and investment for end stage renal disease (ESRD) research.

"The recent DaVita Clinical Research accomplishments can be attributed to our continuous research quality index measurements and commitment to service excellence," said Chris Rucker, DCR Vice President and General Manager. "These values serve as a catalyst for our research objectives, and allow us to participate in the advancement of renal knowledge and practice."

DCR has nearly two decades of experience in conducting Phase I-IV clinical trials, and is the nation's largest renal research network dedicated to providing and supporting clinical and data research. DCR provides Phase-I renal studies services including renal, Hepatic, CV, Dermatology and Endocrine subjects, Pharmacokinetics, Pharmacodynamics and drug interactions. Phase II- IV renal studies services include pre ESRD and ESRD subjects, clinical efficacy and safety, special populations and post marketing studies.

"Since departing full-time academics for private practice, DaVita Clinical Research has helped me to continue my clinical research efforts," said Robert I. Lynn, M.D. of Nephrology & Hypertension Associates. "The staff locates high quality studies and makes it easier to do clinical trials in DaVita(R) facilities. They are friendly, responsive and supportive, and DaVita Clinical Research really does work with you not only to get a research effort 'off the ground,' but also to help it develop and prosper."

DaVita and DaVita Clinical Research are registered trademarks of DaVita Inc. All other trademarks are the properties of their respective owners.

About DaVita Inc.

DaVita Inc., a FORTUNE 500(R) company, is a leading provider of kidney care in the United States, providing dialysis services and education for patients with chronic kidney failure and end stage renal disease. DaVita manages more than 1,300 outpatient facilities and acute units in more than 700 hospitals located in 43 states and the District of Columbia, serving approximately 107,000 patients. For more information about DaVita and its kidney education programs, please visit http://www.davita.com.


'/>"/>
SOURCE DaVita Clinical Research
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Globus Medical Completes Enrollment Of SECURE(R)-C Cervical Artificial Disc Clinical Trial
2. Siemens and LabCorp Enter Agreement to Co-Develop New Clinical Diagnostic Tests
3. Vion Pharmaceuticals Announces Initiation of Clinical Trial of Cloretazine(R) (VNP40101M) in Combination with Cytarabine
4. BiPar Sciences Expands Phase 2 Clinical Trials of BSI-201, a Novel DNA Repair Inhibitor, in Ovarian Cancer
5. Go Healthy Initiates Additional Clinical Tests on Cholesterade
6. Arena Pharmaceuticals, Inc. Announces Initiation of Phase 1 Clinical Trial of Drug Candidate Under Partnership with Taisho Pharmaceutical Co., Ltd.
7. Johnson & Johnson to Provide Webcast Presentation of Tapentadol Phase 3 Clinical Data Presented at American Pain Societys Annual Meeting
8. XTENT Announces Clinical Trial Data to be Presented at Annual EuroPCR Meeting Next Week
9. NKTR-118 Shows Substantial Oral Bioavailability and Extended Half-Life in Phase 1 Clinical Data Presented at American Pain Society Meeting
10. Patients Treated with Risperidone Long-Acting Injection had a Significantly Longer Time to Relapse Compared to Quetiapine in International Clinical Study
11. Association of Clinical Research Organizations (ACRO) to Help Lead Clinical Trials Transformation Initiative
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2017)... 2017 The Institute for In Vitro Sciences ... recipient of a VITROCELL® inhalation exposure system thanks to ... The device, which is designed to replace animals in ... cells to airborne test materials in an environment that ... system for testing combustible tobacco products, as well as ...
(Date:7/6/2017)... CINCINNATI , July 6, 2017 ThriveRx, the nutrition division ... and their families to thrive on nutrition support. To celebrate ... The new site has a fresh new look with improved organization to ... ... ...
(Date:7/5/2017)... Wash. , July 5, 2017   BioLife ... leading developer, manufacturer and marketer of proprietary clinical grade ... cryopreservation freeze media ("BioLife"), today announced that it ... its debt holder and largest shareholder, to modify its ... Pursuant to the modification, WAVI agreed to exchange ...
Breaking Medicine Technology:
(Date:7/22/2017)... ... July 22, 2017 , ... The arthroscopic superior capsule ... opportunity to return to sports and jobs that require heavy physical work, as ... Annual Meeting in Toronto, Ontario, Canada. , “We studied 100 patients ...
(Date:7/21/2017)... Orange Park, FL (PRWEB) , ... July 21, ... ... that provides insurance management assistance and financial planning services to families and business ... in a charity event that promises to provide support to area adults with ...
(Date:7/21/2017)... , ... July 21, 2017 , ... Hospital M&A activity ... HealthCareMandA.com . The number of hospital acquisitions rose to 23 in the second quarter, ... and up 15% from the 20 announced deals in the year-ago second quarter. Only ...
(Date:7/21/2017)... (PRWEB) , ... July 21, 2017 , ... ... 4th-year medical students improve their chances of acceptance to a residency in a ... who have earned degrees outside the U.S. , According to data released by ...
(Date:7/21/2017)... (PRWEB) , ... July 21, 2017 , ... ... anterior cruciate ligament (ACL) offer patients improved quality of life five years after ... Sports Medicine’s Annual Meeting in Toronto, Ontario, Canada. The study followed patients ...
Breaking Medicine News(10 mins):